Replies to post #123812 on Avid Bioservices Inc (CDMO)

[biopharm]

Thanks FTM! one key paragraph out of that article:

Regulators “have good reason to be skeptical about PFS,” says Mario Eisenberger, MD, a professor of oncology and urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD. “There's precedence now showing that drug approvals based on PFS have had to be recalled later,” he says, such as the withdrawal of bevacizumab (Avastin; Genentech) in metastatic breast cancer.

The FDA knows "Safety" is the #1 factor .. right along side Survival and these are the major reasons why Bavituximab should be regarded highly within the FDA... as long as they can do their job without Big Pharma requests.

GLTA!